136 related articles for article (PubMed ID: 9873781)
1. Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group.
Szucs TD; Offner A; Kroner B; Giangrande P; Berntorp E; Schramm W
Haemophilia; 1998 Jul; 4(4):498-501. PubMed ID: 9873781
[TBL] [Abstract][Full Text] [Related]
2. Socioeconomic impact of haemophilia care: results of a pilot study.
Szucs TD; Öffner A; Schramm W
Haemophilia; 1996 Oct; 2(4):211-7. PubMed ID: 27214359
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and resource utilization associated with haemophilia care in Europe.
Schramm W; Royal S; Kroner B; Berntorp E; Giangrande P; Ludlam C; Gringeri A; Berger K; Szucs T;
Haemophilia; 2002 Jan; 8(1):33-43. PubMed ID: 11886463
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
5. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
[TBL] [Abstract][Full Text] [Related]
6. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study.
Shapiro AD; Donfield SM; Lynn HS; Cool VA; Stehbens JA; Hunsberger SL; Tonetta S; Gomperts ED;
Pediatrics; 2001 Dec; 108(6):E105. PubMed ID: 11731632
[TBL] [Abstract][Full Text] [Related]
7. Social/economic costs and quality of life in patients with haemophilia in Europe.
Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
[TBL] [Abstract][Full Text] [Related]
8. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
9. Estimating unknown parameters in haemophilia using expert judgement elicitation.
Fischer K; Lewandowski D; Janssen MP
Haemophilia; 2013 Sep; 19(5):e282-8. PubMed ID: 23672712
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
11. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B
Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
Miners AH; Sabin CA; Tolley KH; Lee CA
Pharmacoeconomics; 2002; 20(11):759-74. PubMed ID: 12201795
[TBL] [Abstract][Full Text] [Related]
13. Cost of severe haemophilia in Toronto.
Heemstra HE; Zwaan T; Hemels M; Feldman BM; Blanchette V; Kern M; Einarson TR
Haemophilia; 2005 May; 11(3):254-60. PubMed ID: 15876271
[TBL] [Abstract][Full Text] [Related]
14. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
Globe DR; Curtis RG; Koerper MA;
Haemophilia; 2004 Mar; 10 Suppl 1():63-70. PubMed ID: 14987251
[TBL] [Abstract][Full Text] [Related]
15. [Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients].
Berger K; Schopohl D; Eheberg D; Oldenburg J; Tiede A; Schramm W
Hamostaseologie; 2014; 34(4):291-300. PubMed ID: 25370177
[TBL] [Abstract][Full Text] [Related]
16. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
[TBL] [Abstract][Full Text] [Related]
17. A comparison between prophylaxis and on demand treatment for severe haemophilia.
Khoriaty R; Taher A; Inati A; Lee C
Clin Lab Haematol; 2005 Oct; 27(5):320-3. PubMed ID: 16178913
[TBL] [Abstract][Full Text] [Related]
18. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
Khawaji M; Astermark J; Berntorp E
Eur J Haematol; 2012 Apr; 88(4):329-35. PubMed ID: 22221195
[TBL] [Abstract][Full Text] [Related]
19. The cost of severe haemophilia in Europe: the CHESS study.
O'Hara J; Hughes D; Camp C; Burke T; Carroll L; Diego DG
Orphanet J Rare Dis; 2017 May; 12(1):106. PubMed ID: 28569181
[TBL] [Abstract][Full Text] [Related]
20. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
